Amifostine - A radioprotector in locally advanced head and neck tumors

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL.4, 1999, Pages 27-29

  Schönekäs, Klaus Gregor ^a   Wagner, Wolfgang ^a   Prott, Franz Josef ^b  

^a Paracelsus Klinik Osnabruck   (Germany)

^b NONE

Author keywords

Amifostine; Head and neck cancer; Radiotherapy; Side effects

Indexed keywords

AMIFOSTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DYSPHAGIA; FEMALE; HEAD TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NAUSEA; NECK TUMOR; RADIATION PROTECTION; VOMITING; XEROSTOMIA;

ADULT; AGED; AMIFOSTINE; DEGLUTITION DISORDERS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PARTICLE ACCELERATORS; POSTOPERATIVE CARE; RADIATION-PROTECTIVE AGENTS; RADIODERMATITIS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SALIVARY GLANDS; TIME FACTORS; XEROSTOMIA;

EID: 0345148941     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bohuslavizki KH, Brenner W, Klutmann S, et al. Radioprotection of salivary glands by amifostine in high-dose radiodine therapy. J Nucl Med 1998;39:1237-42.
2. Büntzel J, Glatzel M, Schuth J, et al. Einsatz von Amifostin hei simultaner Radiochemotherapie von HNO-Tumoren - eine Phase I/II Studie. Z Onkol 1997;2:42-9.
3. Büntzel J, Küttner K, Fröhlich D. et al. Selective cytoprotection with amifostine in concurrent radio-chemotherapy for head and neck cancer. Ann Oncol 1998;9:505-9.
4. Busch M, Schymura B, Dü'hmke E. Cytoprotection with amifostine in recurrent head and neck cancer. Proc Am Soc Clin Oncol 1997;16:1418.
5. Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993;72: 3495-501.
6. Dörr W, Dölling-Jochem I, Baumann M, et al. Therapeutische Beeinflussung der radiogenen oralen Mukositis. Strahlenther Onkol 1997; 173: 183-92.
7. Eilers J, Berger AM, Petersen MC. Development, testing, and application of the Oral Assessment Guide. Oncol Nurs Forum 1988;15:325-30.
8. Füller J, Trog D. Koscielny S, et al. Toxizität der Radiochemotherapie mit prolongierter 5-FU-Dauerinfusion bei inoperablen Tumoren der Kopf-Hals-Region unter Einsatz des Zytoprotektivums Amifostin. Strahlenther Onkol 1997;173:646.
9. McDonald S, Meyerowitz C, Smudzin T, et al. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994;29:747-54.
10. McDonald S. Meyerowitz C, Smudzin T, et al. Amifostine preserves the salivary gland function during irradiation of the head and neck. Eur J Cancer 1995;31a:Suppl 5:415.
11. Mücke R, Peters K, Hamann D, et al. A randomized study of concurrent radiochemotherapy (RCT) versus RCT + amifostine (A) in patients with advanced head and neck tumours: no cytoprotective effect of time limited application of amifostine. Radiother Oncol 1998;48:Suppl 1:117.
12. Treskes M, Nijtmans LGJ, Fichtlinger-Schepman AMJ, et al. The modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 1992; 43:1013-9.
13. Wassermann TH. Radiotherapeutic studies with amifostine (Ethyol). Semin Oncol 1994;21:Suppl 11:21-5.
14. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2(3-aminopropylamino) ethylphorothioic acid. Cancer Res 1980;40:1519-24.